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Few tumour types have received as much molecular analysis as breast
cancer over the past 10 years. Impressive progress has been made in
the analysis and interpretation of genomic data sets, the identification
of novel mechanisms of breast cancer susceptibility, growth and
development and the parallel integration of these molecular data to
test novel therapeutic approaches for patients with this disease within
clinical trials. This book, edited by Giordano and Normanno with
individual chapters from experts in the field, successfully integrates
this diverse field of progress within one volume, suitable for both
medical professionals with an interest in breast cancer management
and scientists with an interest in translational oncology. The book
covers an impressive field, guiding the reader through scientific
developments in breast tumour biology, cell-cycle control and growth
factor signalling, to the complexities of stromal/tumour interactions,
mammary gland development and stem cell biology, through to the
clinical implications of basic research.
A consistent feature of the book is the elegant way in which the
reader is led from the basic science observations underpinning
the evidence through to the clinical implications of bench-side
research. Several chapters review developments in the field from
a clinical practice perspective. Chapter 3 explores the implications
of developments in breast cancer genetics and its application in
clinical practice, succinctly explained by Russo and colleagues. The
authors cover a broad field, describing the molecular portrait of
breast cancer using microarray analysis (also reviewed in detail in
chapter 8) of gene and microRNA expression and the difficulties
implementing such techniques into clinical practice, recently
emphasised by Weigelt et al (2010). The authors present a useful
section on oncogenetic counselling and genotype/phenotype
relationship discussing the implications of distinct BRCA1/2
sequence variants and disease association.
Modelling breast cancer using transgenic mice is discussed in detail
in chapter 7 by Dillon and Muller. The authors present structured
and balanced examples supporting the use of animal models while
expressing caution concerning the key differences between mouse
and human mammary stromal tissue, patterns of cancer spread and
the predominant oestrogen receptor negativity of most animal
models. A future vision of developments in this field is presented,
through the modelling of stromal/tumour interactions and the design
of animal models that more robustly reflect hormone receptor
profiles and patterns of spread witnessed in human breast cancer.
The final four chapters of the book discuss novel targets in breast
cancer, their therapeutic implications and clinical trial considera-
tions when developing drugs targeting these molecules. Lee and
colleagues discuss the complexities of TGF-b signalling and the
Jekyll and Hyde character of this signalling cascade in breast cancer
mediating both tumour suppressor and oncogenic pathway activa-
tion and how this may impact on the successful targeting of this
network. Szyf reviews epigenetic modification through the modi-
fication of gene expression through regional DNA hypermethylation
in chapter 10. DNA methylation is associated with the silencing of
tumour suppressor gene expression and widespread hypomethyl-
ation patterns involving metastasis-associated genes are commonly
witnessed in solid tumours. This chapter presents a balanced view
associated with therapeutic strategies aimed at modulating methyl-
transferase activity in breast cancer, detailing the complexity of
this process mediated by the DNA methyltransferase family and
their targeting to specific DNA positions through interaction with
sequence recognition factors. The author discusses practical
considerations when attempting to influence the activity of this
process, as although DNA methyltransferase blockade may activate
tumour suppressor gene expression, the paradoxical activation of
metastasis-associated gene expression could also be unleashed.
Chapter 11, ‘Signal transduction inhibitors in the treatment of
breast cancer’ by Maiello and colleagues, discusses the clinical trial
results associated with the specific targeting of growth factor receptor
pathways in breast cancer. Despite the excitement of the introduction
of such strategies into clinical trial development in breast cancer,
the authors emphasise that clinical activity associated with notable
monotherapy strategies has been disappointing. Redundancy of
growth factor signalling pathways and inter-patient tumoural
heterogeneity are likely to contribute to these disappointing results.
The only potential criticism of such a book is the rate at which
this field is progressing and how rapidly a second edition is
required to keep up with developments. Perhaps the second
edition will consider the impact of next-generation sequencing
technologies on our understanding of the complexity of breast
cancer tumourigenesis and tumour heterogeneity and the post-
genomic functional annotation of the breast cancer genome using
RNA interference strategies. In summary, Breast Cancer in the
Post-Genomic Era will be highly relevant to both scientists and
oncology health professionals requiring a practical overview of the
field of translational breast cancer medicine.
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